TapewireFind a company

person · Reporting owner

RIGGS RORY B

Disclosed activity across 4 companies

Tapewire entity
41461
SEC CIK
0001016835

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Cibus, Inc.CBUS · Entity 6658DirectorJune 02, 2026June 04, 2026
KYNTRA BIO, INC.FGEN · Entity 7431DirectorMay 26, 2021May 28, 2021
Royalty Pharma plcRPRX · Entity 3100DirectorFebruary 20, 2024February 23, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cibus, Inc.

Report date June 02, 2026 · Filed June 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2036-06-02Direct77,586 Reported balance After 2026-06-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-02 · Grant · Acquired 77,586 · Balance 77,586

F1: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders.

KYNTRA BIO, INC.

Report date May 26, 2021 · Filed May 28, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect395,750 Reported balance After 2021-05-26 transaction · row 1
1 source row

Row 1 · 2021-05-26 · Grant · Acquired 4,700 · Balance 395,750

F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.86 · Expires 2031-05-25Direct7,800 Reported balance After 2021-05-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2021-05-26 · Grant · Acquired 7,800 · Balance 7,800

F3: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Common StockSEC Table I · non-derivativeIndirectSee footnote605,713 Reported balance Holding disclosure · report date 2021-05-26 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 605,713

F2: Shares are held by New Ventures I, LLC. The reporting person is Managing Member of New Ventures I, LLC and has voting and investment control with respect to the shares held by New Ventures I, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

F2: Shares are held by New Ventures I, LLC. The reporting person is Managing Member of New Ventures I, LLC and has voting and investment control with respect to the shares held by New Ventures I, LLC.

F3: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Royalty Pharma plc

Report date February 20, 2024 · Filed February 23, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Ordinary SharesSEC Table I · non-derivativeDirect320,099 Reported balance After 2024-02-20 transaction · row 1
1 source row

Row 1 · 2024-02-20 · Conversion · Acquired 300,000 · Balance 320,099

F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

LP interests in RPI US Partners 2019, LPSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct270,000 Reported balance After 2024-02-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2024-02-20 · Conversion · Disposed 30,000 · Balance 270,000

F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

Class A Ordinary SharesSEC Table I · non-derivativeIndirectBy New Ventures III LLC85,187 Reported balance Holding disclosure · report date 2024-02-20 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 85,187

Class A Ordinary SharesSEC Table I · non-derivativeIndirectBy Spouse15,000 Reported balance Holding disclosure · report date 2024-02-20 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 15,000

Filing footnotes · ownership attribution and instrument terms

F1: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Intra-Cellular Therapies, Inc.

Report date April 02, 2025 · Filed April 02, 2025

Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2025-04-02 transaction · row 1
1 source row

Row 1 · 2025-04-02 · Disposition to issuer · Disposed 131,512 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2025-06-15Direct0 Reported balance After 2025-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.35 · Expires 2026-06-13Direct0 Reported balance After 2025-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.45 · Expires 2027-06-26Direct0 Reported balance After 2025-04-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.45 · Expires 2031-06-20Direct0 Reported balance After 2025-04-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.48 · Expires 2032-06-08Direct0 Reported balance After 2025-04-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-04-02 · Disposition to issuer · Disposed 16,757 · Balance 0

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.79 · Expires 2033-06-22Direct0 Reported balance After 2025-04-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-04-02 · Disposition to issuer · Disposed 7,009 · Balance 0

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13Direct0 Reported balance After 2025-04-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-04-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0

F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share.

F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F7: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share.

F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F7: Not applicable.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 02, 2026 Filed Jun 4, 2026 21:43 UTC Cibus, Inc. CBUS · Entity 6658 GrantStock Option (Right-to-Buy) · Derivative 77,586 $0.00 Strike: $1.39 $0.00
Disclosure

SEC source: 0001615594-26-000042 · primary_doc.xml · derivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,586

Underlying: Class A Common Stock · 77,586 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders.

Read SEC document
January 29, 2026 Filed Feb 3, 2026 01:27 UTC Cibus, Inc. CBUS · Entity 6658 GrantClass A Common Stock 333,333 $1.50 $499,999.50
Disclosure

SEC source: 0001193125-26-034092 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,916,640

F1 · shares: On January 29, 2026, Cibus, Inc. (the "Issuer") entered into an Underwriting Agreement (the "Underwriting Agreement") in connection with a firm commitment underwritten public offering (the "Offering"), which closed on January 30, 2026. The reporting person purchased 333,333 shares of Class A Common Stock in the Offering at the public offering price of $1.50 per share. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3.

Read SEC document
June 09, 2025 Filed Jun 11, 2025 21:11 UTC Cibus, Inc. CBUS · Entity 6658 OtherPre-Funded Warrant (right to buy) · Derivative 50,000 $0.00 Strike: $0.01 $0.00
Disclosure

SEC source: 0000950170-25-084928 · ownership.xml · derivative · entry 6

RIGGS RORY B · CIK 0001016835 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 50,000 shares

Expires not disclosed

F2 · derivative.expiration_date: Pre-funded warrants to purchase Class A Common Stock held by the reporting person have no expiration date.

Read SEC document
June 09, 2025 Filed Jun 11, 2025 21:11 UTC Cibus, Inc. CBUS · Entity 6658 OtherPre-Funded Warrant (right to buy) · Derivative 4,000,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-084928 · ownership.xml · derivative · entry 5

RIGGS RORY B · CIK 0001016835 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 4,000,000 shares

Expires not disclosed

F2 · derivative.expiration_date: Pre-funded warrants to purchase Class A Common Stock held by the reporting person have no expiration date.

Read SEC document
June 09, 2025 Filed Jun 11, 2025 21:11 UTC Cibus, Inc. CBUS · Entity 6658 OtherClass A Common Stock 50,000 $0.01 $500.00
Disclosure

SEC source: 0000950170-25-084928 · ownership.xml · nonDerivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,583,307

Read SEC document
June 09, 2025 Filed Jun 11, 2025 21:11 UTC Cibus, Inc. CBUS · Entity 6658 OtherClass A Common Stock 4,000,000 $0.00 $400.00
Disclosure

SEC source: 0000950170-25-084928 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,533,307

Read SEC document
June 05, 2025 Filed Jun 10, 2025 20:15 UTC Cibus, Inc. CBUS · Entity 6658 GrantClass A Common Stock 5,714,286 $1.75 $10,000,000.50
Disclosure

SEC source: 0000950170-25-084320 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,533,307

F1 · shares: On June 5, 2025, Cibus, Inc. (the "Issuer") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Rory Riggs, the Chairman of the Company's Board of directors, in connection with a public offering conducted on a reasonable "best efforts" basis (the "Offering"). Pursuant to the Purchase Agreement, the Issuer agreed to issue and sell to Mr. Riggs 5,714,286 shares of Class A Common Stock, par value $0.0001 per share, at the public offering price of $1.75 per share. The Offering is expected to be fully consummated on or about June 9, 2025. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3.

F2 · balance_after: Reflects corrections with respect to 20,891 shares of Class A Common Stock that were previously reported as attributable directly to the reporting person that are instead held indirectly through the Rory Riggs Family Trust.

Read SEC document
May 22, 2025 Filed May 27, 2025 19:07 UTC Cibus, Inc. CBUS · Entity 6658 GrantStock Option (Right-to-Buy) · Derivative 39,301 $0.00 Strike: $2.77 $0.00
Disclosure

SEC source: 0001615594-25-000073 · primary_doc.xml · derivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,301

Underlying: Class A Common Stock · 39,301 shares

Expires 2035-05-22

F1 · derivative.exercise_date: The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of the shareholders

Read SEC document
April 02, 2025 Filed Apr 2, 2025 21:47 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Disposition to issuerRestricted Stock Units · Derivative 2,951 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-049648 · ownership.xml · derivative · entry 9

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,951 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share.

F6 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F6 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F7 · derivative.expiration_date: Not applicable.

Read SEC document
April 02, 2025 Filed Apr 2, 2025 21:47 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Disposition to issuerStock Option (right to buy) · Derivative 4,322 Not disclosed Strike: $67.77 Not disclosed
Disclosure

SEC source: 0000950170-25-049648 · ownership.xml · derivative · entry 8

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,322 shares

Expires 2034-06-13

F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Read SEC document
April 02, 2025 Filed Apr 2, 2025 21:47 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Disposition to issuerStock Option (right to buy) · Derivative 7,009 Not disclosed Strike: $63.79 Not disclosed
Disclosure

SEC source: 0000950170-25-049648 · ownership.xml · derivative · entry 7

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,009 shares

Expires 2033-06-22

F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Read SEC document
April 02, 2025 Filed Apr 2, 2025 21:47 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Disposition to issuerStock Option (right to buy) · Derivative 16,757 Not disclosed Strike: $55.48 Not disclosed
Disclosure

SEC source: 0000950170-25-049648 · ownership.xml · derivative · entry 6

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,757 shares

Expires 2032-06-08

F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Read SEC document
April 02, 2025 Filed Apr 2, 2025 21:47 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Disposition to issuerStock Option (right to buy) · Derivative 20,000 Not disclosed Strike: $43.45 Not disclosed
Disclosure

SEC source: 0000950170-25-049648 · ownership.xml · derivative · entry 5

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2031-06-20

F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Read SEC document
April 02, 2025 Filed Apr 2, 2025 21:47 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Disposition to issuerStock Option (right to buy) · Derivative 20,000 Not disclosed Strike: $12.45 Not disclosed
Disclosure

SEC source: 0000950170-25-049648 · ownership.xml · derivative · entry 4

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2027-06-26

F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Read SEC document
April 02, 2025 Filed Apr 2, 2025 21:47 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Disposition to issuerStock Option (right to buy) · Derivative 20,000 Not disclosed Strike: $38.35 Not disclosed
Disclosure

SEC source: 0000950170-25-049648 · ownership.xml · derivative · entry 3

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2026-06-13

F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Read SEC document
April 02, 2025 Filed Apr 2, 2025 21:47 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Disposition to issuerStock Option (right to buy) · Derivative 20,000 Not disclosed Strike: $26.58 Not disclosed
Disclosure

SEC source: 0000950170-25-049648 · ownership.xml · derivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2025-06-15

F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · price: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4 · derivative.exercise_date: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

Read SEC document
April 02, 2025 Filed Apr 2, 2025 21:47 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Disposition to issuerCommon Stock 131,512 $132.00 $17,359,584.00
Disclosure

SEC source: 0000950170-25-049648 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2 · kind: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2 · price: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

Read SEC document
January 21, 2025 Filed Jan 23, 2025 21:19 UTC Cibus, Inc. CBUS · Entity 6658 GrantPre-Funded Warrant · Derivative 4,000,000 $2.50 Strike: $0.00 $9,999,600.00
Disclosure

SEC source: 0000950170-25-008350 · ownership.xml · derivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000,000

Underlying: Class A Common Stock · 4,000,000 shares

Expires not disclosed

F1 · kind: On January 21, 2025, Cibus, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Rory Riggs, the Company's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs 4,000,000 pre-funded warrants to purchase shares of Class A Common Stock, par value $0.0001 ("Class A Common Stock"), and an accompanying common warrant to purchase up to 4,000,000 shares of Class A Common Stock at a combined offering price of $2.4999. The Purchase Agreement was entered into in connection with the Company's registered direct offering, which is expected to be fully consummated on or about January 24, 2025. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3.

F1 · price: On January 21, 2025, Cibus, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Rory Riggs, the Company's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs 4,000,000 pre-funded warrants to purchase shares of Class A Common Stock, par value $0.0001 ("Class A Common Stock"), and an accompanying common warrant to purchase up to 4,000,000 shares of Class A Common Stock at a combined offering price of $2.4999. The Purchase Agreement was entered into in connection with the Company's registered direct offering, which is expected to be fully consummated on or about January 24, 2025. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3.

F3 · derivative.exercise_date: Pre-Funded Warrants have no expiration date, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $0.0001 per share of Class A Common Stock and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Issuer's outstanding common stock.

F3 · derivative.expiration_date: Pre-Funded Warrants have no expiration date, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $0.0001 per share of Class A Common Stock and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Issuer's outstanding common stock.

Read SEC document
January 21, 2025 Filed Jan 23, 2025 21:19 UTC Cibus, Inc. CBUS · Entity 6658 GrantCommon Warrant · Derivative 4,000,000 Not disclosed Strike: $2.50 Not disclosed
Disclosure

SEC source: 0000950170-25-008350 · ownership.xml · derivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000,000

Underlying: Class A Common Stock · 4,000,000 shares

Expires not disclosed

F1 · kind: On January 21, 2025, Cibus, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Rory Riggs, the Company's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs 4,000,000 pre-funded warrants to purchase shares of Class A Common Stock, par value $0.0001 ("Class A Common Stock"), and an accompanying common warrant to purchase up to 4,000,000 shares of Class A Common Stock at a combined offering price of $2.4999. The Purchase Agreement was entered into in connection with the Company's registered direct offering, which is expected to be fully consummated on or about January 24, 2025. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3.

F1 · price: On January 21, 2025, Cibus, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Rory Riggs, the Company's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs 4,000,000 pre-funded warrants to purchase shares of Class A Common Stock, par value $0.0001 ("Class A Common Stock"), and an accompanying common warrant to purchase up to 4,000,000 shares of Class A Common Stock at a combined offering price of $2.4999. The Purchase Agreement was entered into in connection with the Company's registered direct offering, which is expected to be fully consummated on or about January 24, 2025. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3.

F2 · derivative.exercise_date: Common Warrants issued to Mr. Riggs may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $2.4999 per share of Class A Common Stock, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Company's outstanding common stock. The Common Warrants will not be exercisable until the Company receives certain approvals from its stockholders (the "Warrant Stockholder Approvals") required by the applicable rules of the Nasdaq Capital Market. The Common Warrants will expire five years following the date of receipt of the Warrant Stockholder Approvals.

F2 · derivative.expiration_date: Common Warrants issued to Mr. Riggs may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $2.4999 per share of Class A Common Stock, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Company's outstanding common stock. The Common Warrants will not be exercisable until the Company receives certain approvals from its stockholders (the "Warrant Stockholder Approvals") required by the applicable rules of the Nasdaq Capital Market. The Common Warrants will expire five years following the date of receipt of the Warrant Stockholder Approvals.

Read SEC document
December 31, 2024 Filed Jan 3, 2025 23:01 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 GrantCommon Stock 215 $83.52 $17,956.80
Disclosure

SEC source: 0000950170-25-001440 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,512

Read SEC document
December 31, 2024 Filed Jan 10, 2025 14:51 UTC Cibus, Inc. CBUS · Entity 6658 ConversionCibus Common Unit · Derivative 1,388,084 Not disclosed Not disclosed
Disclosure

SEC source: 0001615594-25-000004 · primary_doc.xml · derivative · entry 5

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,388,084 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement.

F3 · price: Pursuant to the Exchange Agreement, the reporting person exchanged Up-C Units for the same number of shares of Class A Common Stock.

F5 · price: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement.

F5 · derivative.exercise_date: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement.

F5 · derivative.expiration_date: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement.

F3 · ownership.direct: Pursuant to the Exchange Agreement, the reporting person exchanged Up-C Units for the same number of shares of Class A Common Stock.

F5 · ownership.direct: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement.

Read SEC document
December 31, 2024 Filed Jan 10, 2025 14:51 UTC Cibus, Inc. CBUS · Entity 6658 ConversionClass A Common Stock 1,388,084 Not disclosed Not disclosed
Disclosure

SEC source: 0001615594-25-000004 · primary_doc.xml · nonDerivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,839,912

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Up-C Units are generally exchangeable for shares of the Issuer's Class A Common Stock on a 1-for-1 basis pursuant to an Exchange Agreement dated May 31, 2023 by and among the Issuer, Cibus Global LLC, and the holders of Up-C Units.

F3 · price: Pursuant to the Exchange Agreement, the reporting person exchanged Up-C Units for the same number of shares of Class A Common Stock.

Read SEC document
December 31, 2024 Filed Jan 10, 2025 14:51 UTC Cibus, Inc. CBUS · Entity 6658 ConversionClass B Common Stock 1,388,084 Not disclosed Not disclosed
Disclosure

SEC source: 0001615594-25-000004 · primary_doc.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each share of Class B Common Stock of Cibus, Inc. is paired with a common unit of Cibus Global LLC, which collectively comprise an Up-C Unit.

F2 · price: The Up-C Units are generally exchangeable for shares of the Issuer's Class A Common Stock on a 1-for-1 basis pursuant to an Exchange Agreement dated May 31, 2023 by and among the Issuer, Cibus Global LLC, and the holders of Up-C Units.

Read SEC document
September 30, 2024 Filed Oct 2, 2024 22:01 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 GrantCommon Stock 246 $73.17 $17,999.82
Disclosure

SEC source: 0000950170-24-111766 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,108

Read SEC document
September 18, 2024 Filed Sep 20, 2024 21:48 UTC Cibus, Inc. CBUS · Entity 6658 GrantClass A Common Stock 250,000 $4.00 $1,000,000.00
Disclosure

SEC source: 0000950170-24-108504 · ownership.xml · nonDerivative · entry 3

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,451,828

F2 · shares: On September 18, 2024, the Company entered into an Underwriting Agreement (the "Underwriting Agreement") in connection with a firm commitment underwritten public offering (the "Offering"), which closed on September 19, 2024. The reporting person purchased 250,000 shares of Class A Common Stock in the Offering at the public offering price of $4.00.

Read SEC document
June 28, 2024 Filed Jul 3, 2024 00:00 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 GrantCommon Stock 262 $68.49 $17,944.38
Disclosure

SEC source: 0000950170-24-080986 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,862

Read SEC document
June 24, 2024 Filed Jun 25, 2024 22:04 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Exercise / conversionStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $16.86 $0.00
Disclosure

SEC source: 0000950170-24-077468 · ownership.xml · derivative · entry 5

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2024-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: On June 24, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024 and the issuer retained 4,462 shares of common stock to pay the exercise price of the options.

F4 · derivative.exercise_date: This option was granted on June 30, 2014 and will expire on June 30, 2024. All shares underlying this option have vested.

Read SEC document
June 24, 2024 Filed Jun 25, 2024 22:04 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 SaleCommon Stock 4,462 $75.57 $337,193.34
Disclosure

SEC source: 0000950170-24-077468 · ownership.xml · nonDerivative · entry 3

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,600

F2 · shares: On June 24, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024 and the issuer retained 4,462 shares of common stock to pay the exercise price of the options.

Read SEC document
June 24, 2024 Filed Jun 25, 2024 22:04 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Exercise / conversionCommon Stock 20,000 $16.86 $337,200.00
Disclosure

SEC source: 0000950170-24-077468 · ownership.xml · nonDerivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: On June 24, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024 and the issuer retained 4,462 shares of common stock to pay the exercise price of the options.

Read SEC document
June 23, 2024 Filed Jun 25, 2024 22:04 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Exercise / conversionRestricted Stock Units · Derivative 1,567 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077468 · ownership.xml · derivative · entry 4

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,567 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F3 · derivative.exercise_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024).

F3 · derivative.expiration_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024).

Read SEC document
June 23, 2024 Filed Jun 25, 2024 22:04 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Exercise / conversionCommon Stock 1,567 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-077468 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
June 14, 2024 Filed Jun 18, 2024 22:02 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 GrantStock Option (right to buy) · Derivative 4,322 $0.00 Strike: $67.77 $0.00
Disclosure

SEC source: 0000950170-24-075081 · ownership.xml · derivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,322

Underlying: Common Stock · 4,322 shares

Expires 2034-06-13

Read SEC document
June 14, 2024 Filed Jun 18, 2024 22:02 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 GrantRestricted Stock Units · Derivative 2,951 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-075081 · ownership.xml · derivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,951

Underlying: Common Stock · 2,951 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2 · derivative.exercise_date: On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025).

F2 · derivative.expiration_date: On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025).

Read SEC document
June 11, 2024 Filed Jun 14, 2024 10:53 UTC Cibus, Inc. CBUS · Entity 6658 GrantCommon Warrant · Derivative 98,040 Not disclosed Strike: $10.07 Not disclosed
Disclosure

SEC source: 0000950170-24-073319 · ownership.xml · derivative · entry 4

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,040

Underlying: Class A Common Stock · 98,040 shares

Expires 2029-06-13

F3 · derivative.exercise_price: Represents the consolidated closing bid price on the Nasdaq Capital Market on June 11, 2024.

F2 · kind: On June 11, 2024, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with Rory Riggs, the Issuer's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs (i) 98,040 shares of Class A Common Stock and an accompanying common warrant to purchase Class A Common Stock at a combined offering price of $10.20. The Purchase Agreement was entered into in connection with the Issuer's registered direct offering, which is expected to close with respect to Mr. Riggs on or about June 13, 2024. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3.

F2 · price: On June 11, 2024, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with Rory Riggs, the Issuer's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs (i) 98,040 shares of Class A Common Stock and an accompanying common warrant to purchase Class A Common Stock at a combined offering price of $10.20. The Purchase Agreement was entered into in connection with the Issuer's registered direct offering, which is expected to close with respect to Mr. Riggs on or about June 13, 2024. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3.

F4 · derivative.exercise_date: Common Warrants issued to Mr. Riggs will expire on June 13, 2029, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $10.07 per share of Class A Common Stock, and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Company's outstanding common stock.

Read SEC document
June 11, 2024 Filed Jun 14, 2024 10:53 UTC Cibus, Inc. CBUS · Entity 6658 GrantClass A Common Stock 98,040 $10.20 $1,000,008.00
Disclosure

SEC source: 0000950170-24-073319 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,201,828

F2 · balance_after: On June 11, 2024, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with Rory Riggs, the Issuer's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs (i) 98,040 shares of Class A Common Stock and an accompanying common warrant to purchase Class A Common Stock at a combined offering price of $10.20. The Purchase Agreement was entered into in connection with the Issuer's registered direct offering, which is expected to close with respect to Mr. Riggs on or about June 13, 2024. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3.

Read SEC document
March 31, 2024 Filed Apr 2, 2024 20:15 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 GrantCommon Stock 260 $69.20 $17,992.00
Disclosure

SEC source: 0000950170-24-040165 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,495

Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:12 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Exercise / conversionStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $18.56 $0.00
Disclosure

SEC source: 0000950170-24-035358 · ownership.xml · derivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2024-03-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: On March 21, 2014, the reporting person was granted options to purchase 20,000 shares of common stock, vesting as to 50% of the shares on January 8, 2015 and as to the remainder of the shares on January 8, 2016.

Read SEC document
March 20, 2024 Filed Mar 22, 2024 20:12 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 Exercise / conversionCommon Stock 20,000 $18.56 $371,200.00
Disclosure

SEC source: 0000950170-24-035358 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,235

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 20, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that were expiring on March 21, 2024.

Read SEC document
February 20, 2024 Filed Feb 23, 2024 00:23 UTC Royalty Pharma plc RPRX · Entity 3100 ConversionLP interests in RPI US Partners 2019, LP · Derivative 30,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001802768-24-000014 · wk-form4_1708647785.xml · derivative · entry 4

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 270,000

Underlying: Class A Ordinary Shares · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

Read SEC document
February 20, 2024 Filed Feb 23, 2024 00:23 UTC Royalty Pharma plc RPRX · Entity 3100 ConversionClass A Ordinary Shares 300,000 $0.00 $0.00
Disclosure

SEC source: 0001802768-24-000014 · wk-form4_1708647785.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,099

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

Read SEC document
January 04, 2024 Filed Jan 4, 2024 22:16 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 35,702 $27.55 $983,504.42
Disclosure

SEC source: 0001802768-24-000002 · wk-form4_1704406578.xml · nonDerivative · entry 3

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,099

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.36 to $27.79 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 03, 2024 Filed Jan 4, 2024 22:16 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 199,098 $27.79 $5,532,276.40
Disclosure

SEC source: 0001802768-24-000002 · wk-form4_1704406578.xml · nonDerivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,801

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.48 to $28.26 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:16 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 235,200 $28.52 $6,707,080.80
Disclosure

SEC source: 0001802768-24-000002 · wk-form4_1704406578.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 254,899

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.79 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
December 31, 2023 Filed Jan 3, 2024 23:46 UTC Intra-Cellular Therapies, Inc. ITCI · Entity 81206 GrantCommon Stock 251 $71.62 $17,976.62
Disclosure

SEC source: 0000950170-24-001305 · ownership.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,235

Read SEC document
December 29, 2023 Filed Jan 4, 2024 00:08 UTC Cibus, Inc. CBUS · Entity 6658 ConversionCibus Common Units · Derivative 1,500,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-24-000057 · doc4.xml · derivative · entry 9

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,367,193

Underlying: Class A Common Stock · 1,500,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement.

F4 · kind: Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership.

F4 · shares: Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership.

F4 · price: Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership.

F7 · derivative.exercise_date: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement.

F7 · derivative.expiration_date: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement.

F8 · balance_after: Includes 1,361,226 Common Units, as part of Up-C Units, previously reported by the Reporting Person and 5,967 Common Units, as part of the Up-C Units received in the Distribution and not exchanged in the Reporting Person Exchange.

Read SEC document
December 29, 2023 Filed Jan 4, 2024 00:08 UTC Cibus, Inc. CBUS · Entity 6658 OtherCibus Common Units · Derivative 1,505,967 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-24-000057 · doc4.xml · derivative · entry 8

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,867,193

Underlying: Class A Common Stock · 1,505,967 shares

Expires not disclosed

F7 · derivative.exercise_price: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement.

F2 · kind: Each share of the Issuer's Class B Common Stock, par value $0.0001 (the "Class B Common Stock") is paired with a common unit (the "Common Units") of Cibus Global, LLC ("Cibus Global"), which collectively comprise an "Up-C Unit." The Up-C Units are generally exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement (the "Exchange Agreement"), dated May 31, 2023, by and among the Issuer, Cibus Global, and the holders of Up-C Units. On December 29, 2023, New Ventures Agtech Solutions, LLC ("New Ventures") completed a distribution to the Reporting Person of 1,505,967 Up-C Units (the "Distribution"). Such Up-C Units were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures and the other investors in New Ventures.

F3 · kind: (Continued from Footnote 2) Simultaneously with the Distribution, the Reporting Person exchanged 1,500,000 shares of such Up-C Units for 1,500,000 shares of Class A Common Stock (the "Reporting Person Exchange") in accordance with the Exchange Agreement, Accordingly, although the Reporting Person's aggregate beneficial ownership has not changed, this Form reports the change in the Reporting Person's beneficial ownership both in name and form.

F7 · price: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement.

F7 · derivative.exercise_date: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement.

F7 · derivative.expiration_date: Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement.

Read SEC document
December 29, 2023 Filed Jan 4, 2024 00:08 UTC Cibus, Inc. CBUS · Entity 6658 ConversionClass A Common Stock 1,500,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-24-000057 · doc4.xml · nonDerivative · entry 6

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,103,788

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership.

F4 · price: Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership.

F6 · balance_after: Includes 1,603,788 shares of Class A Common Stock previously reported by the Reporting Person and 1,500,000 shares of Class A Common Stock received pursuant to the Reporting Person Exchange.

Read SEC document
December 29, 2023 Filed Jan 4, 2024 00:08 UTC Cibus, Inc. CBUS · Entity 6658 ConversionClass B Common Stock 1,500,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-24-000057 · doc4.xml · nonDerivative · entry 5

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,367,193

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership.

F4 · price: Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership.

F5 · balance_after: Includes 1,361,226 shares of Class B Common Stock, as part of Up-C Units, previously reported by the Reporting Person and 5,967 shares of Class B Common Stock, as part of the Up-C Units received in the Distribution and not exchanged in the Reporting Person Exchange.

Read SEC document
December 29, 2023 Filed Jan 4, 2024 00:08 UTC Cibus, Inc. CBUS · Entity 6658 OtherClass B Common Stock 1,505,967 $0.00 $0.00
Disclosure

SEC source: 0000899243-24-000057 · doc4.xml · nonDerivative · entry 4

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,867,193

F2 · kind: Each share of the Issuer's Class B Common Stock, par value $0.0001 (the "Class B Common Stock") is paired with a common unit (the "Common Units") of Cibus Global, LLC ("Cibus Global"), which collectively comprise an "Up-C Unit." The Up-C Units are generally exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement (the "Exchange Agreement"), dated May 31, 2023, by and among the Issuer, Cibus Global, and the holders of Up-C Units. On December 29, 2023, New Ventures Agtech Solutions, LLC ("New Ventures") completed a distribution to the Reporting Person of 1,505,967 Up-C Units (the "Distribution"). Such Up-C Units were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures and the other investors in New Ventures.

F3 · kind: (Continued from Footnote 2) Simultaneously with the Distribution, the Reporting Person exchanged 1,500,000 shares of such Up-C Units for 1,500,000 shares of Class A Common Stock (the "Reporting Person Exchange") in accordance with the Exchange Agreement, Accordingly, although the Reporting Person's aggregate beneficial ownership has not changed, this Form reports the change in the Reporting Person's beneficial ownership both in name and form.

Read SEC document
December 12, 2023 Filed Dec 14, 2023 22:10 UTC Cibus, Inc. CBUS · Entity 6658 OtherPre-Funded Warrant · Derivative 50,000 $10.57 Strike: $0.01 $528,500.00
Disclosure

SEC source: 0000950170-23-070459 · ownership.xml · derivative · entry 3

RIGGS RORY B · CIK 0001016835 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Class A Common Stock · 50,000 shares

Expires not disclosed

F3 · kind: On December 11, 2023, the Issuer entered into an Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity LLC, as underwriters in respect of an underwritten registered direct offering (the "Underwritten Offering"). Pursuant to the Underwritten Offering, the underwriters placed (i) 517,107 shares of Class A Common Stock to Mr. Riggs at a purchase price of $10.58; (ii) 2,106,723 shares of Class A Common Stock to certain other investors at a purchase price of $9.00; and (iii) 50,000 Pre-Funded Warrants to purchase 50,000 shares of Class A Common Stock ("Pre-Funded Warrants") to Mr. Riggs at a purchase price of $10.57 per Pre-Funded Warrant. On December 14, 2023, the Issuer consummated the Underwritten Offering.

F3 · price: On December 11, 2023, the Issuer entered into an Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity LLC, as underwriters in respect of an underwritten registered direct offering (the "Underwritten Offering"). Pursuant to the Underwritten Offering, the underwriters placed (i) 517,107 shares of Class A Common Stock to Mr. Riggs at a purchase price of $10.58; (ii) 2,106,723 shares of Class A Common Stock to certain other investors at a purchase price of $9.00; and (iii) 50,000 Pre-Funded Warrants to purchase 50,000 shares of Class A Common Stock ("Pre-Funded Warrants") to Mr. Riggs at a purchase price of $10.57 per Pre-Funded Warrant. On December 14, 2023, the Issuer consummated the Underwritten Offering.

F4 · derivative.exercise_date: Pre-Funded Warrants have no expiration date, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $0.01 per share of Class A Common Stock and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Issuer's outstanding common stock.

F4 · derivative.expiration_date: Pre-Funded Warrants have no expiration date, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $0.01 per share of Class A Common Stock and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Issuer's outstanding common stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.